Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share allocation details.
Key transaction details include:
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Dividend Date: 14 January 2016.
- Share Price: 1,367.57 pence per Share.
- Notification Date: GSK was informed of allocations on 28 January 2016.
Material Changes
The filing details specific increases in shareholdings for the following individuals due to the dividend re-investment plan:
- Directors/PDMRs: Sir Andrew Witty (28,610 shares), Mr S Dingemans (937,309 shares), Mr S A Hussain (30,863 shares), Mr D S Redfern (813,543 shares), Dr M M Slaoui (164,460 shares), Ms C Thomas (998,661 shares), Mr P C Thomson (341,837 shares), Dr P J T Vallance (1,210,723 shares), and Ms E Walmsley (939,015 shares).
- Connected Persons: Mrs K Thomson (Connected to Mr P C Thomson) acquired 110,075 shares.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. It is a regulatory disclosure of director share transactions only.
Investor Verification Checklist
- Verify the total number of shares acquired by each Director and PDMR listed in the filing.
- Confirm the share price of 1,367.57 pence used for the dividend re-investment on 14 January 2016.
- Review the full list of connected persons to ensure all related party transactions are accounted for.
- Note that this filing contains no financial performance metrics; refer to the most recent Form 20-F or quarterly results for financial data.